Abstract
Background A number of disorders caused by copy number variants (CNVs) are associated with a high risk of neurodevelopmental and psychiatric disorders and cognitive impairments (ND-CNVs). Few studies of ND-CNVs have investigated the emotional and behavioural problems that are important outcomes in young people with developmental and intellectual disabilities using appropriate measures.
Methods 322 young people with 13 ND-CNVs across eight loci (mean age:9.79 years, range:6.02-17.91, 66.5% male) took part in the study. Primary carers completed the Developmental Behaviour Checklist (DBC).
Results Sixty-seven percent of individuals with an ND-CNV screened positive for clinically significant difficulties. Young people from families with higher incomes (OR=0.71, CI=0.55 – 0.92, p=.009) were less likely to screen positive. Young people born after prolonged labour (OR=2.87, CI=1.18-8.13, p=.030) were more likely to screen positive. The rate of difficulties differed depending on ND-CNV genotype (Deviance=25.83, p=.011), with the lowest rate in 22q11.2 deletion (46%) and the highest in 1q21.1 deletion (87.5%). Individuals with inherited ND-CNVs had greater difficulties (F=6.54, df=1, p=.012, ηp2=.050), including higher self-absorbed (F=5.01, df=1, p=.027, ηp2=.039) and communication disturbance scores (F=9.13, df=1, p=.003, ηp2=.068). Specific patterns of strengths and weaknesses were found for different ND-CNV genotypes. However, ND-CNV genotype explained no more than 7-16% of variance, depending on subdomain.
Conclusions Behavioural and emotional problems are common in young people with ND-CNVs. The ND-CNV specific patterns we find can provide a basis for more tailored support. More research is needed to better understand the variation in behavioural and emotional problems not accounted for by genotype.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding: This research was funded by MRC grant Intellectual Disability and Mental Health: Assessing Genomic Impact on Neurodevelopment (IMAGINE) (MR/N022572/1 and MR/L011166/1; JH, MvdB and MO), a Wellcome Trust Strategic Award ‘Defining Endophenotypes From Integrated Neurosciences (DEFINE) (503147 MO and JH), Medical Research Council Programme Grant (G0800509; MO), the National Institute of Mental Health (NIMH 5UO1MH101724; MvdB and MO), a Wellcome Trust Institutional Strategic Support Fund (ISSF) award (MvdB), the Waterloo Foundation (918-1234; MvdB), and an early career fellowship from the Waterloo Foundation Changing Minds programme awarded to AC, the Baily Thomas Charitable Fund (2315/1; MvdB and TRUST/VC/AC/SG/5196-8188; MvdB) and Health & Care Research Wales (Welsh Government, 507556).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of Interest: None
Ethical standards: The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
Funding: This research was funded by MRC grant Intellectual Disability and Mental Health: Assessing Genomic Impact on Neurodevelopment (IMAGINE) (MR/N022572/1 and MR/L011166/1; JH, MvdB and MO), a Wellcome Trust Strategic Award ‘Defining Endophenotypes From Integrated Neurosciences (DEFINE) (503147 MO and JH), Medical Research Council Programme Grant (G0800509; MO), the National Institute of Mental Health (NIMH 5UO1MH101724; MvdB and MO), a Wellcome Trust Institutional Strategic Support Fund (ISSF) award (MvdB), the Waterloo Foundation (918-1234; MvdB), and an early career fellowship from the Waterloo Foundation Changing Minds programme awarded to AC, the Baily Thomas Charitable Fund (2315/1; MvdB and TRUST/VC/AC/SG/5196-8188; MvdB) and Health & Care Research Wales (Welsh Government, 507556).
Data Availability
Data Available on request
